Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 98 publications.

Craig T, Baptist A, Anderson J, Zaragoza-Urdaz R, Burnette A, Kelbel T, Riedl M, Vanegas A, Boyle K, Schultz B, Blair C, Sing K, Fox D, Juethner S. Patient-reported outcomes among patients with hereditary angioedema within underrepresented racial or ethnic groups. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB81.

Dolin P, Kielar D, Shavit A, Koegh K, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen S. Comorbidities in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 23, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB53.

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg L, Nham T, Chen S. Healthcare resource utilization and costs in patients with eosinophilic granulomatosis with polyangiitis versus severe uncontrolled asthma: a retrospective analysis of US health insurance claims data. Poster presented at the 2024 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting; February 25, 2024. Washington, DC. [abstract] J Allergy Clin Immunol. 2024 Feb; 153(2):AB206.

Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S. Long-term impact of the gene therapy etranacogene dezaparvovec for the treatment of hemophilia B in the United States. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S36-7.

Fan Q, Hawe E, Yang J, Burgess B, Bullano M, Mokdad A. Cost outcomes of noninhibitor patients with hemophilia A switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies in the United States. Poster presented at the AMCP Nexus 2023; October 16, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S35.

Chinthammit C, Mody R, Aguado J, Meyers J. Does weight loss in addition to HbA1c reduction impact health care costs in patients treated with T2D? a retrospective database analysis. Poster presented at the AMCP 2023 Annual Meeting; March 21, 2023. San Antonio, TX. [abstract] J Manag Care Pharm. 2023 Mar; 29(10-2):S27.

Huang MY, Smith A, Brister T, Counts N, Sweeney C, McSorley D, Suthoff E, Parikh S. Report from a national survey of depression treatment: patient experience on antidepressant medications for major depressive disorder. Poster presented at the AMCP Nexus 2022; October 11, 2022. National Harbor, MD. [abstract] J Manag Care Pharm. 2022 Oct; 28(10-a):S59-60.

Hu A, Kwon M, Chung L, Rastegar J, Stevens L, Schwab P. HIV prep adherence on incidence of HIV diagnosis in a national health plan population. Poster presented at the 2022 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 29, 2022. Chicago, IL. [abstract] J Manag Care Pharm. 2022 Mar; 28(3-a):S88.

Alpert C, Rhodes C, Stevens L, Ellis JJ, Johnson S, Schwab P. Evaluation of pharmacist-led interventions for patients flagged for high morphine milligram equivalents (MME). Poster presented at the 2022 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 29, 2022. Chicago, IL. [abstract] J Manag Care Pharm. 2022 Mar; 28(3-a):S93.

Patel SM, Schwab P, Garcia B, Ellis JJ, Vaccaro J. Description of vaccination status and incidence of shingles. Poster presented at the 2022 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 29, 2022. Chicago, IL. [abstract] J Manag Care Pharm. 2022 Mar; 28(3-a):S88.

Huang I, Schwab P, Wojcicki S, Poonawalla I, Ellis JJ, Racsa P. Febrile neutropenia risk and health care costs in members receiving low-risk antineoplastic regimens with and without granulocyte colony stimulating factor primary prophylaxis support. Poster presented at the 2022 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 29, 2022. Chicago, IL. [abstract] J Manag Care Pharm. 2022 Mar; 28(3-a):S88.

Sanders C, Schwab P, Poonawalla I, Grebe L, Sassack K, Kennedy K, Vaccaro J, Ellis J. A real-world characterization of adverse drug events of Bruton tyrosine kinase inhibitors. Poster presented at the 2021 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 13, 2022. [abstract] J Manag Care Pharm. 2022 Mar; 28(3-a).

Klepitskaya O, Serbin M, Sutphin J, Leach C, Mansfield C, Yonan C, Sheehan M, Donnelly A. Development of a patient survey on preferences for adjunctive parkinson's disease medications: results from pretest interviews. Poster presented at the AMCP Nexus 2021; October 18, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S8.

Xiao H, Blum S, Davenport E, Wang J, Hunter S, Li M, Kondo K. Health care resource utilization of patients with advanced gastric cancer/gastroesophageal junction cancer or esophageal adenocarcinoma: results of nivolumab plus chemotherapy versus chemotherapy from CheckMate 649. Poster presented at the AMCP Nexus 2021; October 18, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S19.

Gold BD, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Treatment burden and associated costs in adolescents and adults with eosinophilic esophagitis in the USA. Poster presented at the AMCP Nexus 2021; October 19, 2021. [abstract] J Manag Care Pharm. 2021 Oct; 27(10-a):S82.

Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget-impact of adding darolutamide to a United States payer formulary for non-metastatic castration-resistant prostate cancer. Poster presented at the 2020 AMCP (Conference cancelled); April 21, 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr 20; 26(4-a):S18.

Aggarwal K, Vredenburg M, Mladsi D, Barnett C. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 2020 AMCP Meeting (Conference cancelled); April 2020. [abstract] J Manag Care Pharm. 2020 Apr; 26(Supplement 4a):s58.

Obimah A, Goyal RK, Bhansali A, Sansgiry SS. Can intervention tools with better message framing lead to better intention: a case of chemoprevention for breast cancer. Poster presented at the 2020 AMCP (Conference cancelled); April 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr; 26(4-a):S89.

Parikh R, Niyazov A, Esterberg E, Arondekar B, Arruda L, Obeid E. Real-World treatment patterns and safety outcomes among patients with HER2 negative advanced breast cancer and BRCA1/2 mutations: evidence from a retrospective medical record review study in the United States. Poster presented at the 2020 AMCP (Conference cancelled); April 21, 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr; 26(4-a):S16.

Thach A, Sutphin J, Coulter J, Mansfield C. Patient experiences and preferences for specific on-demand treatments for Parkinson's Disease-related “OFF” episodes. Poster presented at the 2020 AMCP (Conference cancelled); April 21, 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr; 26(4-a):S40.

Burte E, Leynaert B, Marcon A, Bousquet J, Benmerad M, Bono R, Carsin AE, de Hoogh K, Forsberg B, Gormand F, Heinrich J, Just J, Nieuwenhuijsen M, Pin I, Stempfelet M, Sunyer J, Villani S, Kunzli N, Siroux V, Jarvis D, Nadif R, Jacquemin B. Long-term air pollution exposure is associated with increased severity of rhinitis in 2 European cohorts. J Allergy Clin Immunol. 2020 Mar;145(3):834-842.e. doi: 10.1016/j.jaci.2019.11.040

Horter L, Dickinson E, Harvey R, Schwab P, Ward M, Sehman M. Treatment patterns in new user cohorts of non-specialty first-line therapy for immune-mediated inflammatory diseases. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a):S81.

DiBenedetti D, Tzivelekis S, Meckley L. Humanistic cost impacts associated with immunoglobulin replacement therapy among patients with primary immunodeficiency disease in the United States. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a Suppl):S37.

Yun S, Schwab P, Piazza B, Dickinson E. Exploration of proportion of days covered thresholds for medical cost offset /outcomes among patients using inhaled therapies for moderate to severe chronic obstructive pulmonary disease. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a):S11.

Bugner C, Vaccaro J, Schwab P, Cornett D, Drzayich Jankus D, Martinez Vasquez D, Harris J, Sethi M, Cole B. Real-world comparative effectiveness, safety, and health care costs of Sacubitril/ Valsartan versus Angiotensin-II receptor blockers in a Medicare population. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a):S10.

Nag A, Olayinka-Amao B, Martin S, Purser M, Mladsi D. The humanistic burden of chronic idiopathic constipation in the US: a systematic review. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a Suppl):S17.

Meckley L, Coles T, Williams N, DiBenedetti D, McLeod L. Experience with immunoglobulin treatment among patients with PIDD in the US. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting; February 22, 2019. San Francisco, CA. [abstract] J Allergy Clin Immunol. 2019 Feb; 143(2 Supplement):AB112. doi: 10.1016/j.jaci.2018.12.341

Nguyen AM, Muccino D, Birring S, Bacci ED, Vernon MK, Mines D, Smith JA. Defining minimal clinically important differences (MCID) in chronic cough: analyses of objective cough counts from a phase 2 randomized controlled trial. Poster presented at the 2019 Annual Meeting of the American Academy of Asthma, Allergy and Immunology; February 2019. [abstract] J Allergy Clin Immunol. 2019 Feb; 143(2 Supplement):AB169. doi: 10.1016/j.jaci.2018.12.519

Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. Budget impact of introducing tildrakizumab for the treatment of moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):s78.

Nagar SP, Fan Y, Meyers J, Tighe RM. Real-world treatment patterns of nintedanib among patients with idiopathic pulmonary fibrosis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S71.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.

Raspa M, Sacco P, Bailey DB, Visootsak J, Cabo R. Clinical unmet needs and burden in Fragile X syndrome: results of a targeted literature review. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr 24; 24(4-a):S7. Previously presented at the American Association on Intellectual and Development Disabilities 141st Annual Meeting.

Parikh R, Clancy Z, Candrilli S, Parikh K. Administrative data algorithms to identify diagnosis and treatment-related measures in patients with multiple myeloma: a validation study. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-2):S29.

Chiang J, Schwab P, McCulloch R, Brooks P, Rhodes C, Happe L. Impact of a retrospective drug utilization review program on changing opioid prescribing behavior. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S11.

Graham C, McGuire M, Knox H, Ung B. Budget impact analysis of enasidenib treatment in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S31.

Krishnarajah G, Knox H, Graham CN, Christiansen S, Zuraw B. Subcutaneous C1-inhibitor prophylactic treatment for hereditary angioedema: a budget impact model. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S37.

Sacco P, Raspa M, Leahy L, Cabo R. A literature review of the economic burden of Fragile X syndrome. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S7. Previously presented at the 70th AAN Annual Meeting.

Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.

Buck PO, Curran D, Patterson BJ, Varghese L, van Oorschot D, Carrico J, Hicks K, Lee BY, Yawn BP. Cost-effectiveness of adjuvanted recombinant zoster vaccine (RZV) for vaccinating US adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.

Guerra S, Melen E, Sunyer J, Xu CJ, Lavi I, Benet M, Bustamante M, Carsin AE, Dobano C, Guxens M, Tischer C, Vrijheid M, Kull I, Bergstrom A, Kumar A, Soderhall C, Gehring U, Dijkstra D, van der Vlies P, Wickman M, Bousquet J, Postma DS, Anto JM, Koppelman GH. Genetic and epigenetic regulation of YKL-40 in childhood. J Allergy Clin Immunol. 2018 Mar;141(3):1105-14. doi: 10.1016/j.jaci.2017.06.030

Devercelli G, Davis K, Brown M, Hollis K, Hunter S, Long J, Jain G, Banerji A. Burden of hereditary angioedema: findings from a US patient survey. Poster presented at the 2018 AAAAI/WAO Joint Congress; March 3, 2018. Orlando, FL. [abstract] J Allergy Clin Immunol. 2018 Feb; 141(2 Suppl):AB57. doi: 10.1016/j.jaci.2017.12.182

Mansfield C, Gebben D, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S, Shah N. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Pharm. 2017 Oct; 23(10-a):S55.

Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study of moderate-to-severe asthma. J Allergy Clin Immunol. 2017 May;139(5):1489-1495. doi: 10.1016/j.jaci.2016.07.038.

Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 May;139(5):1678-80. doi: 10.1016/j.jaci.2016.12.953

Raghunathan K, Layton JB, Ohnuma T, Shaw AD. Observational research using propensity scores. Adv Chronic Kidney Dis. 2016 Nov;23(6):367-72. doi: 10.1053/j.ackd.2016.11.010

Swanger C, Tobbe C, Schwab PE, Lane D, Hurwitch A. Opioid utilization patterns in a humana commercial and medicare population. Poster presented at the 2016 Academy of Managed Care Pharmacy's 28th Annual Meeting & Expo; October 3, 2016. National Harbor, MD. [abstract] J Manag Care Pharm. 2016 Oct; 22(10-a).

Willson T, Montejano L, Wollschlaeger B, Ronquest N, Nadipelli V. Real-world dosing patterns among patients receiving buprenorphine for opioid dependence in the United States. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S60.

Hogue SL, Silvia S, Hollis K, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 19, 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S116. Previously presented at the 2016 ACAAI Conference.

Graham J, Xuan D, Luthra R, Borker R, Earnshaw SE, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S30.